J. Grosset

发表

Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice

N. Lounis, Abdelhalim Bentoucha, C. Truffot-Pernot, 2001, Antimicrobial Agents and Chemotherapy.

Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene

S. Cole, S. Waddell, P. Butcher, 2012 .

Targeting DnaN for tuberculosis therapy using novel griselimycins

H. Matter, D. Heinz, R. Müller, 2015, Science.

Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection

J. Grosset, J. Alffenaar, T. S. van der Werf, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Rifampicin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection in Ghana

J. Grosset, J. Alffenaar, D. Almeida, 2008 .

Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection

J. Grosset, P. Converse, D. Almeida, 2010, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis

R. Chaisson, W. Bishai, J. Grosset, 2002, Antimicrobial Agents and Chemotherapy.

Impact of iron loading and iron chelation on murine tuberculosis

N. Lounis, J. Grosset, C. Maslo, 1999 .

In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis

N. Lounis, C. Truffot-Pernot, B. Ji, 1998, Antimicrobial Agents and Chemotherapy.

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal

Thomas Abeel, Qiandong Zeng, Bruce W. Birren, 2015, PLoS medicine.

Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis.

W. Sougakoff, J. Grosset, J. Derenne, 1998, American journal of respiratory and critical care medicine.

Adverse effects of rifampin.

J. Grosset, S. Leventis, 1983, Reviews of infectious diseases.

In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.

C. Truffot-Pernot, B. Ji, J. Grosset, 1991, Tubercle.

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

R. Chaisson, W. Bishai, R. O'brien, 2004, American journal of respiratory and critical care medicine.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice

W. Bishai, J. Grosset, A. Pym, 2014, Mycobacterial diseases : tuberculosis & leprosy.

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

W. Jacobs, J. Grosset, S. Tyagi, 2012, The Indian journal of medical research.

Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections

P. Karakousis, J. Grosset, G. Bisson, 2011, Antimicrobial Agents and Chemotherapy.

Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples.

K. Feldmann, S. Rüsch-Gerdes, V. Jarlier, 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

B. Dautzenberg, S. Chevret, J. Grosset, 1991, The American review of respiratory disease.

Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice.

W. Bishai, G. Lamichhane, P. Karakousis, 2007, The Journal of infectious diseases.

Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

J. Grosset, P. Converse, D. Almeida, 2011, Future microbiology.

PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis

H. Derendorf, J. Grosset, C. Peloquin, 2010, Antimicrobial Agents and Chemotherapy.

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

Koen Andries, Thomas Ioerger, J. Sacchettini, 2016, Antimicrobial Agents and Chemotherapy.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis

R. Chaisson, V. Saini, J. Grosset, 2018, Antimicrobial Agents and Chemotherapy.

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

R. Chaisson, W. Bishai, R. O'brien, 2004, American journal of respiratory and critical care medicine.

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

Y. Amoako, P. Saunderson, F. Sarfo, 2020, The Lancet.

Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy

N. Lounis, C. Truffot-Pernot, B. Ji, 1992, Antimicrobial Agents and Chemotherapy.

Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection.

J. Grosset, R. Parrot, Robert G. Parrot, 1988, Tubercle.

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

J. Grosset, P. Converse, S. Tyagi, 2013, The Journal of antimicrobial chemotherapy.

Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak

J. Desenclos, J. Grosset, V. Vincent, 2001, The Lancet.

New drugs for the treatment of tuberculosis: hope and reality.

W. Bishai, J. Grosset, T. G. Singer, 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

P. Karakousis, J. Grosset, K. Mdluli, 2012, Antimicrobial Agents and Chemotherapy.

The chemotherapy of leprosy: an interpretive history.

J. Grosset, R. Gelber, 2012, Leprosy review.

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

J. Grosset, C. Peloquin, P. Converse, 2011, American journal of respiratory and critical care medicine.

Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis

J. Grosset, S. Tyagi, D. Almeida, 2009, Antimicrobial Agents and Chemotherapy.

Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model

R. Chaisson, W. Bishai, J. Grosset, 2007, PLoS medicine.

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

W. Bishai, J. Grosset, A. Vernon, 2006, American journal of respiratory and critical care medicine.

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

W. Bishai, J. Grosset, A. Vernon, 2005, American journal of respiratory and critical care medicine.

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

W. Bishai, J. Grosset, S. Tyagi, 2005, American journal of respiratory and critical care medicine.

Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections

J. Grosset, E. Nuermberger, 2004, European Journal of Clinical Microbiology and Infectious Diseases.

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.

G. Hejblum, N. Lounis, C. Truffot-Pernot, 2000, American journal of respiratory and critical care medicine.

Clarithromycin is inactive against Mycobacterium tuberculosis

N. Lounis, C. Truffot-Pernot, B. Ji, 1995, Antimicrobial agents and chemotherapy.

Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida.

B. Dautzenberg, T. Doco‐Lecompte, J. Grosset, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex

C. Truffot-Pernot, B. Ji, J. Grosset, 1991, Antimicrobial Agents and Chemotherapy.

Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS.

J. Grosset, L. Heifets, J. Craft, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease

J. Grosset, M. Dailloux, J. Maugein, 2005, European Respiratory Journal.

Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice

J. Robert, N. Lounis, Abdelhalim Bentoucha, 2001, Antimicrobial Agents and Chemotherapy.

Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1992, Antimicrobial Agents and Chemotherapy.

Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1991, Antimicrobial Agents and Chemotherapy.

Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.

J. Robert, C. Truffot-Pernot, J. Grosset, 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer

J. Grosset, P. Converse, D. Almeida, 2018, Antimicrobial Agents and Chemotherapy.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

V. Saini, M. Rudek, Nicole M. Anders, 2018, PLoS neglected tropical diseases.

Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome.

B. Dautzenberg, S. De Wit, J. Grosset, 1993, Archives of internal medicine.

A randomized comparison of two clarithromycin doses for treatment ofMycobacterium avium complex infections

B. Dautzenberg, C. Chastang, C. Truffot-Pernot, 1997, Infection.

Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1995, Antimicrobial agents and chemotherapy.

Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease)

J. Grosset, C. Johnson, E. Nuermberger, 2007, Antimicrobial Agents and Chemotherapy.

Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans

C. Horsfield, J. Grosset, R. Phillips, 2005, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice

V. Jarlier, J. Robert, Abdelhalim Bentoucha, 2002, Antimicrobial Agents and Chemotherapy.

Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice.

N. Lounis, C. Truffot-Pernot, B. Ji, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model

N. Lounis, C. Truffot-Pernot, B. Ji, 1995, Antimicrobial agents and chemotherapy.

Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice

J. Grosset, J. Pocidalo, C. Perronne, 1993, Antimicrobial Agents and Chemotherapy.

Disseminated Mycobacterium avium intracellulare infection without predisposing conditions

B. Autran, J. Grosset, J. Clauvel, 1992, The Lancet.

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1990, Antimicrobial Agents and Chemotherapy.

The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.

P. Karakousis, J. Grosset, C. Peloquin, 2010, The Journal of antimicrobial chemotherapy.

Prevention of the Selection of Clarithromycin-Resistant Mycobacterium avium-intracellulare Complex

B. Ji, J. Grosset, 2012, Drugs.

Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model

N. Lounis, C. Truffot-Pernot, B. Ji, 1994, Antimicrobial Agents and Chemotherapy.

Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.

B. Dautzenberg, C. Katlama, W. Rozenbaum, 1991, Tubercle.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

J. Grosset, P. Converse, S. Tyagi, 2015, Proceedings of the National Academy of Sciences.

Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of Tuberculosis

J. Grosset, B. Ngcobo, D. Almeida, 2015, Antimicrobial Agents and Chemotherapy.

Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)

J. Grosset, N. Ammerman, 2013, Expert review of anti-infective therapy.

New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series].

W. Bishai, J. Grosset, T. G. Singer, 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

New drugs for tuberculosis treatment.

J. Grosset, E. Villarino, F. Sánchez, 2011, Enfermedades infecciosas y microbiologia clinica.

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

J. Grosset, C. K. Stover, S. Tyagi, 2009, American journal of respiratory and critical care medicine.

Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis

J. Grosset, S. Tyagi, E. Nuermberger, 2008, Antimicrobial Agents and Chemotherapy.

Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

J. Grosset, C. Peloquin, S. Tyagi, 2013, American journal of respiratory and critical care medicine.

How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

N. Lounis, C. Truffot-Pernot, B. Ji, 1996, Antimicrobial agents and chemotherapy.

Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice

N. Lounis, J. Grosset, J. Pocidalo, 1995, Antimicrobial agents and chemotherapy.

Assessment of new therapies for infection due to the Mycobacterium avium complex: appropriate use of in vitro and in vivo testing.

J. Grosset, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.

J. Rouby, V. Jarlier, J. Grosset, 1992, The American review of respiratory disease.

Multidrug resistant tuberculosis in France 1992-4: two case-control studies

J. Grosset, V. Vincent, B. Decludt, 1998, BMJ.

Nosocomial transmission of tuberculosis among mentally-handicapped patients in a long-term care facility.

V. Jarlier, W. Sougakoff, J. Grosset, 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model

W. Bishai, J. Grosset, Ronggai Sun, 2005, Antimicrobial Agents and Chemotherapy.

Guidelines for the Management of Drug-resistant Tuberculosis

D. Maher, J. Grosset, M. Iseman, 1997 .

Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

V. Jarlier, W. Sougakoff, C. Truffot-Pernot, 1994, The Journal of infectious diseases.

Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?

D. van Soolingen, J. Grosset, M. Raviglione, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation].

J. Grosset, G. Canetti, N. Rist, 1963, Revue de tuberculose et de pneumologie.

The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

J. Grosset, 1978, Bulletin of the International Union against Tuberculosis.

Mycobacterial Growth Indicator Tube Versus the Proportion Method on Löwenstein-Jensen Medium for Antibiotic Susceptibility Testing of Mycobacterium tuberculosis

V. Jarlier, C. Truffot-Pernot, J. Grosset, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study.

V. Jarlier, J. Robert, J. Grosset, 1999, American journal of respiratory and critical care medicine.

[Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area].

J. Grosset, G. Decroix, C. Sors, 1971, Revue de tuberculose et de pneumologie.

Is PCR a useful tool for the diagnosis of tuberculosis in 1995?

J. Grosset, Y. Mouton, 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

W. Bishai, J. Grosset, P. Converse, 2013, American journal of respiratory and critical care medicine.

A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia.

J. Rouby, J. Grosset, P. Viars, 1989, Anesthesiology.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis

R. Chaisson, V. Saini, J. Grosset, 2019, Antimicrobial Agents and Chemotherapy.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis

R. Chaisson, V. Saini, J. Grosset, 2019, Antimicrobial Agents and Chemotherapy.

Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea Pigs

P. Illei, P. Karakousis, J. Grosset, 2012, Antimicrobial Agents and Chemotherapy.

Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

J. Grosset, C. K. Stover, S. Tyagi, 2008, Antimicrobial Agents and Chemotherapy.

Role of the dosR-dosS Two-Component Regulatory System in Mycobacterium tuberculosis Virulence in Three Animal Models

W. Bishai, G. Lamichhane, P. Karakousis, 2008, Infection and Immunity.

Harnessing the full sterilising activity of rifamycins [Editorial].

J. Grosset, C. Leung, W. Yew, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Treatment of tuberculosis and optimal dosing schedules

J. Grosset, C. Leung, W. Yew, 2010, Thorax.

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.

P. Olliaro, C. Truffot-Pernot, B. Ji, 1993, The American review of respiratory disease.

Present status of chemotherapy for tuberculosis.

J. Grosset, 1989, Reviews of infectious diseases.

Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig

P. Karakousis, J. Grosset, C. Peloquin, 2010, The Journal of antimicrobial chemotherapy.

Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy.

B. Ji, J. Grosset, P. Bobin, 1993, The Journal of infectious diseases.

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++

P. Saunderson, J. Grosset, M. Sturkenboom, 2018, BMC Infectious Diseases.

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

J. Grosset, S. Tyagi, D. Almeida, 2008, Antimicrobial Agents and Chemotherapy.

C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa

P. Drain, J. Grosset, C. Wallis, 2018, AIDS.

Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease

J. Grosset, P. Converse, S. Tyagi, 2014, PLoS neglected tropical diseases.

Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with Autoluminescent Mycobacterium ulcerans Infection

J. Grosset, P. Converse, E. Nuermberger, 2013, PLoS neglected tropical diseases.

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

C. Truffot-Pernot, B. Ji, J. Grosset, 1993, Antimicrobial Agents and Chemotherapy.

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

N. Lounis, C. Truffot-Pernot, B. Ji, 1995, Antimicrobial agents and chemotherapy.

Bacteriologic basis of short-course chemotherapy for tuberculosis.

J. Grosset, 1980, Clinics in chest medicine.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo

J. Grosset, B. Ngcobo, D. Almeida, 2017, The Journal of antimicrobial chemotherapy.

A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

A. Vernon, J. Grosset, 2015, American journal of respiratory and critical care medicine.

Deux cas d'infections successives a Streptococcus pneumoniae

J. Grosset, J. Nguyen, C. Féger, 1990 .

Experimental results on chloroquine and AIDS-related opportunistic infections.

D. Taramelli, R. Appelberg, N. Lounis, 2001, Journal of acquired immune deficiency syndromes.

Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.

N. Lounis, C. Truffot-Pernot, J. Grosset, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group.

É. Carpentier, J. Grosset, F. Doucet-Populaire, 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis

W. Bishai, J. Grosset, S. Tyagi, 2007, Antimicrobial Agents and Chemotherapy.

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

C. Truffot-Pernot, J. Grosset, H. Lecoeur, 1989, The American review of respiratory disease.

Iron and Mycobacterium tuberculosis infection.

V. Gordeuk, N. Lounis, C. Truffot-Pernot, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa.

E. Caumes, C. Truffot-Pernot, J. Grosset, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The management of thirty immunocompromised patients with tuberculosis.

B. Dautzenberg, J. Grosset, S. Herson, 1984, The American review of respiratory disease.

Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system.

Nicholas A. Be, W. Bishai, G. Lamichhane, 2008, The Journal of infectious diseases.

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

J. Grosset, E. Nuermberger, Tianyu Zhang, 2009, American journal of respiratory and critical care medicine.

Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1992, Antimicrobial Agents and Chemotherapy.

Chloroquine does not enhance the activity of clarithromycin against multiplication of Mycobacterium avium within human macrophages.

C. Truffot-Pernot, J. Grosset, J. Pocidalo, 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

The Impact of Mouse Passaging of Mycobacterium tuberculosis Strains prior to Virulence Testing in the Mouse and Guinea Pig Aerosol Models

W. Bishai, G. Lamichhane, D. Geiman, 2010, PloS one.

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments.

C. Truffot-Pernot, B. Ji, J. Grosset, 1991, Tubercle.

Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.

J. Grosset, E. Perani, B. Ji, 1990, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers.

V. Jarlier, W. Sougakoff, C. Truffot-Pernot, 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy

J. Grosset, B. Ngcobo, D. Almeida, 2016, Antimicrobial Agents and Chemotherapy.

Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.

P. Karakousis, J. Grosset, S. Tyagi, 2011, The Journal of antimicrobial chemotherapy.

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

J. Grosset, D. Almeida, E. Nuermberger, 2008, American journal of respiratory and critical care medicine.

Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis

W. Bishai, N. Lounis, J. Grosset, 2005, Antimicrobial Agents and Chemotherapy.

Fluoroquinolones, tuberculosis, and resistance.

W. Bishai, J. Grosset, A. Ginsburg, 2003, The Lancet. Infectious diseases.

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

Stewart T. Cole, Claudia Sala, Vadim Makarov, 2009, Science.

Genomics and the chemotherapy of leprosy.

S. Cole, J. Grosset, 2001, Leprosy review.

MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

P HAUDUROY, D. Mitchison, J. Grosset, 1963, Bulletin of the World Health Organization.

Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease

C. Robinson, F. Sarfo, J. Grosset, 2013, PLoS neglected tropical diseases.

Bactericidal Activities of HMR 3647, Moxifloxacin, and Rifapentine against Mycobacterium leprae in Mice

Abdelhalim Bentoucha, B. Ji, J. Grosset, 2000, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of a Single-Dose Combination of Ofloxacin plus Minocycline, with or without Rifampin, against Mycobacterium leprae in Mice and in Lepromatous Patients

B. Ji, J. Grosset, C. Lienhardt, 1998, Antimicrobial Agents and Chemotherapy.

Response to treatment by multidrug regimens in the THELEP controlled clinical drug trials. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

P. Christie, J. Grosset, M. Waters, 1996, Leprosy review.

Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients

B. Ji, J. Grosset, C. Lienhardt, 1996, Antimicrobial agents and chemotherapy.

Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy

B. Ji, J. Grosset, E. Perani, 1994, Antimicrobial Agents and Chemotherapy.

Primary dapsone resistance in Bamako and Chingleput: final report; THELEP. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

R. Rees, J. Grosset, M. Waters, 1987, Leprosy review.

Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations

J. Grosset, P. Converse, S. Tyagi, 2015, Antimicrobial Agents and Chemotherapy.

A Guinea Pig Model of TB Chemotherapy.

P. Karakousis, J. Grosset, Z. Ahmad, 2009, ATS 2009.

Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital.

V. Jarlier, J. Grosset, J. Nguyen, 1984, The Journal of antimicrobial chemotherapy.

Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets.

Jun O. Liu, W. Bishai, G. Lamichhane, 2010, Chemistry & biology.

PRIMARY DRUG RESISTANCE IN TUBERCULOSIS.

J. Grosset, G. Canetti, N. Rist, 1964, The American review of respiratory disease.

A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae.

A. Telenti, S. Cole, N. Honoré, 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

WHO Expert Committee on Leprosy.

B. Bloom, J. Grosset, M. Waters, 2012, World Health Organization technical report series.

Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin.

J. Grosset, J. Guillaume, B. Flageul, 1989, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Nine cases of rifampin-resistant leprosy.

J. Grosset, G. Brucker, C. C. Guelpa-Lauras, 1984, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

The new challenges for chemotherapy research.

J. Grosset, 2000, Leprosy review.

Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years.

J. Grosset, J. Cartel, L. Nguyen, 2000, Leprosy review.

A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae.

S. Cole, N. Honoré, J. Grosset, 2001, Leprosy review.

A case of relapse with drug-susceptible M. leprae after multidrug therapy.

J. Grosset, H. Sansarricq, J. Carolina, 1991, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice

B. Ji, J. Grosset, E. Perani, 1996, Antimicrobial agents and chemotherapy.

Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice

B. Ji, J. Grosset, E. Perani, 1991, Antimicrobial Agents and Chemotherapy.

Recent advances in the chemotherapy of leprosy.

B. Ji, J. Grosset, 1990, Leprosy review.

Adjuvant immunotherapy with nonviable mycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients

F. Grémy, C. Chastang, B. Asselain, 1984, Cancer.

A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis

Karl W. Broman, Deborah E. Geiman, Gyanu Lamichhane, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial.

S. Chanteau, J. Roux, J. Grosset, 1990, Leprosy review.

Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin.

S. Chanteau, J. Roux, J. Boutin, 1989, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

C. Truffot-Pernot, B. Ji, J. Grosset, 1992, Antimicrobial Agents and Chemotherapy.

Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of M. leprae infection in populations of the South Pacific Islands.

S. Chanteau, J. Roux, J. Boutin, 1990, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease

J. Grosset, P. Converse, S. Tyagi, 2015, PLoS neglected tropical diseases.

Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy.

J. Grosset, 1986, Leprosy review.

BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse

J. Grosset, P. Converse, D. Almeida, 2011, PLoS neglected tropical diseases.

Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy.

B. Ji, J. Grosset, 1999, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years.

S. Chanteau, J. Roux, P. Glaziou, 1992, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

The challenge of tuberculosis: statements on global control and prevention Global control

E. Hershfield, S. Cole, R. O'brien, 1995, The Lancet.

Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.

W. Bishai, P. Karakousis, J. Grosset, 2009, The Journal of infectious diseases.

Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide.

J. Grosset, J. Cartel, J. Millan, 1983, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries.

S. Rüsch-Gerdes, V. Jarlier, J. Grosset, 2005, Microbial drug resistance.

Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary

J. Grosset, 2003, Antimicrobial Agents and Chemotherapy.

Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice

W. Bishai, G. Lamichhane, P. Karakousis, 2004, The Journal of experimental medicine.

Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG

W. Bishai, J. Grosset, S. Tyagi, 2004, Infection and Immunity.

Clarithromycin, Minocycline, and Rifabutin Treatments before and after Infection of C57BL/6 Mice with Mycobacterium avium

J. Grosset, J. Pocidalo, C. Perronne, 1993, Antimicrobial Agents and Chemotherapy.

Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium

J. Grosset, J. Pocidalo, C. Perronne, 1993, Antimicrobial Agents and Chemotherapy.

[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].

J. Fermanian, J. Grosset, H. Lecoeur, 1982, Pathologie et biologie.

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

N. Lounis, C. Truffot-Pernot, B. Ji, 1997, Antimicrobial agents and chemotherapy.

Experimental Chemotherapy of Mycobacterial Diseases

B. Ji, J. Grosset, 1998 .

A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France.

V. Jarlier, J. Robert, C. Truffot-Pernot, 1999, The International Journal of Tuberculosis and Lung Disease.

Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice

V. Jarlier, J. Robert, N. Lounis, 2001, Antimicrobial Agents and Chemotherapy.

Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice

V. Jarlier, J. Grosset, P. Bonnafous, 2000, Antimicrobial Agents and Chemotherapy.

Whither short-course chemotherapy for leprosy?

J. Grosset, 1997, Indian journal of leprosy.

New experimental regimens for preventive therapy of tuberculosis.

J. Grosset, 1990, Bulletin of the International Union against Tuberculosis and Lung Disease.

Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends.

A. Spiegel, J. Grosset, P. Martin, 1992, Leprosy review.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

Thomas Abeel, Abigail L Manson, Ashlee M Earl, 2016, Nature Genetics.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

W. Bishai, S. Swindells, U. Lalloo, 2012, Proceedings of the National Academy of Sciences.

FURTHER EXPERIMENTS ON LONG-TERM CHEMOTHERAPY OF ADVANCED MURINE TUBERCULOSIS, WITH EMPHASIS ON INTERMITTENT REGIMES.

J. Grosset, G. Canetti, F. Grumbach, 1964, Tubercle.

Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage.

J. Grosset, G. Canetti, F. Grumbach, 1963, Tubercle.

Short course chemotherapy in experimental tuberculosis.

J. Grosset, 1978 .

Current problems with tuberculosis treatment.

J. Grosset, 1996, Research in microbiology.

Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations.

M. Felten, J. Grosset, M. Raviglione, 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa

Q. Zeng, B. Birren, A. McGuire, 2015 .

Surveillance of drug resistance for tuberculosis control: why and how?

J. Grosset, P. Chaulet, F. Boulahbal, 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[Routine use of 6-month antitubercular treatment in 300 patients].

J. Grosset, A. Levy, C. Sors, 1986, Presse medicale.

Clinical experience in Algeria of intermittent treatment of pulmonary tuberculosis with isoniazid and streptomycin twice-weekly.

J. Grosset, P. Chaulet, D. Larbaoui, 1968, Tubercle.

Intermittent chemotherapy with isoniazid and streptomycin in Algiers.

J. Grosset, P. Chaulet, D. Larbaoui, 1967, Tubercle.

Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model.

J. Grosset, G. Canetti, M. le Lirzin, 1967, Tubercle.

Modeling In Vivo Pharmacokinetics and Pharmacodynamics of Moxifloxacin Therapy for Mycobacterium tuberculosis Infection by Using a Novel Cartridge System

W. Bishai, J. Grosset, F. Hamzeh, 2005, Antimicrobial Agents and Chemotherapy.

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

C. Truffot-Pernot, B. Ji, R. O'brien, 1994, American journal of respiratory and critical care medicine.

Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.

N. Lounis, C. Truffot-Pernot, B. Ji, 1998, American journal of respiratory and critical care medicine.

Erratum: Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice (American Journal of Respiratory and Critical Care Medicine (1993) 148 (1541-1546))

P. Olliaro, C. Truffot-Pernot, B. Ji, 1994 .

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice

N. Lounis, C. Truffot-Pernot, B. Ji, 1997, Antimicrobial agents and chemotherapy.

Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study

B. Heym, S. T. Cole, W. Jacobs, 1994, The Lancet.

Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy.

J. Grosset, 1981, Chest.

[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].

C. Truffot-Pernot, J. Grosset, H. Lecoeur, 1983, Revue francaise des maladies respiratoires.

Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid.

J. Grosset, G. Canetti, F. Grumbach, 1960, The American review of respiratory disease.

Treatment of tuberculosis in HIV infection.

J. Grosset, 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Charles M Heilig, Dick Menzies, John L. Johnson, 2009, American journal of respiratory and critical care medicine.

New antibacterial drugs for the treatment of mycobacterial disease in man.

D. Mitchison, J. Grosset, G. Ellard, 1988, British medical bulletin.

Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection).

J. Grosset, A. Dinh-Xuan, C. Truffot, 1992, The European respiratory journal.

Infection à Mycobacterium ulcerans

O. Chosidow, V. Jarlier, J. Grosset, 2000 .

Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.

P. Lagrange, C. Truffot-Pernot, J. Grosset, 1989, Clinical and experimental immunology.

Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia.

S. Chanteau, P. Glaziou, J. Grosset, 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Erratum: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis (American Journal of Respiratory and Critical Care Medicine (2004) 169 (421-426))

R. Chaisson, W. Bishai, R. O'brien, 2005 .

Mycobacterium avium Complex Common-Source or Cross-Infection in AIDS Patients Attending the Same Day-Care Facility

C. Katlama, V. Jarlier, C. Truffot-Pernot, 1998, Infection Control & Hospital Epidemiology.

SESSION III. DEVELOPMENTS AND FUTURE ASPECTS

J. Grosset, Enno Freerksen Frg, ET Jhgross, 2014 .

Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis

J. Grosset, C. Peloquin, Z. Ahmad, 2011, Antimicrobial Agents and Chemotherapy.

Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

J. Grosset, M. Waters, J. M. Pearson, 1987, Leprosy review.

Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin.

J. Grosset, J. Cartel, J. Artus, 1985, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Microbial persistence in mycobacterial infections

J. Grosset, H. Lecoeur, C. C. Guelpa-Lauras, 1983 .

The role of low dosage prothionamide with and without 4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis.

J. Grosset, C. Boval, C. Truffot, 1982, Tubercle.

Effectiveness of pefloxacin in the treatment of lepromatous leprosy.

J. Grosset, E. Perani, C. C. Guelpa-Lauras, 1990, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Activity of ofloxacin against Mycobacterium leprae in the mouse.

J. Grosset, E. Perani, C. C. Guelpa-Lauras, 1988, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse.

J. Grosset, E. Perani, C. C. Guelpa-Lauras, 1987, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Variations of teicoplanin concentrations in neutropenic patients

V. Leblond, J. Grosset, A. Thuillier, 1997, Journal of Clinical Pharmacy and Therapeutics.

Rapid Assessment of Antibacterial Activity against Mycobacterium ulcerans by Using Recombinant Luminescent Strains

W. Bishai, J. Grosset, E. Nuermberger, 2010, Antimicrobial Agents and Chemotherapy.

Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of Tuberculosis

W. Bishai, J. Grosset, C. Peloquin, 2006, Antimicrobial Agents and Chemotherapy.

Erratum: Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium (Antimicrobial Agents and Chemotherapy 37:8 (1690))

J. Grosset, J. Pocidalo, C. Perronne, 1993 .

[Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].

C. Truffot-Pernot, J. Grosset, L. Maury, 1988, Revue des maladies respiratoires.

New approaches in antimycobacterial chemotherapy

J. Grosset, 1988 .

Reply to “Contradictory Results with High-Dosage Rifamycin in Mice and Humans”

P. Karakousis, J. Grosset, C. Peloquin, 2013, Antimicrobial Agents and Chemotherapy.

Leprosy and BCG in southern Vietnam

L. Abel, P. Lagrange, J. Grosset, 1990, The Lancet.

Harnessing the full sterilising activity of rifamycins.

J. Grosset, C. Leung, W. Yew, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination.

B. Hubert, J. Grosset, V. Schwoebel, 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin.

V. Jarlier, C. Truffot-Pernot, J. Grosset, 1995, The Journal of antimicrobial chemotherapy.

Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease

J. Grosset, P. Converse, S. Tyagi, 2013, PLoS neglected tropical diseases.

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice

K. Dooley, J. Grosset, P. Converse, 2011, PLoS neglected tropical diseases.

Antibacterial Treatment of Leprosy

J. Grosset, 2005 .

TUBERCULOSE CUTANEE: ETUDE DE 4 CAS

J. Grosset, E. Cambau, F. Bricaire, 1997 .

Bacteriology of tuberculosis

J. Grosset, 1993 .

Impact of BCG on tuberculous meningitis in France in 1990

B. Hubert, J. Grosset, V. Schwoebel, 1992, The Lancet.

FAUT-IL VACCINER PAR LE BCG?

J. Grosset, 1990 .

Advances in Tuberculosis Preventive Therapy

J. Grosset, R. O'Brien, 1997 .

Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.

J. Grosset, J. Cartel, I. Mané, 1997, International journal of leprosy and other mycobacterial diseases.

Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.

B. Ji, J. Grosset, E. Perani, 1992, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice.

B. Ji, J. Grosset, E. Perani, 1994, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.

B. Ji, J. Grosset, 2000, Leprosy review.

History of drug discovery: early evaluation studies and lessons learnt from them.

J. Grosset, Z. Ahmad, Nusrat Habib Makaya, 2011 .

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

W. Bishai, J. Grosset, P. Converse, 2013, American journal of respiratory and critical care medicine.

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

S. Cole, S. Waddell, P. Butcher, 2009, Science.

[Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis].

V. Jarlier, W. Sougakoff, J. Grosset, 1996, Pathologie-biologie.

Leprosy in French Polynesia. Epidemiological trends between 1946 and 1987.

P. Glaziou, J. Boutin, A. Spiegel, 1992, Leprosy review.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

B. Birren, J. Wortman, A. Earl, 2016, Nature Genetics.